Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 10 Roll-out of new-generation insulin portfolio is progressing Key launch observations • TresibaⓇ launched in 47 countries with solid penetration in markets with similar reimbursement as insulin glargine TresibaⓇ value share of basal insulin segment 40% in selected countries, excluding the USA Switzerland Japan Mexico Netherlands Spain Denmark UK Argentina Brazil India Greece Italy 40% • RyzodegⓇ launched in Mexico, India, Bangladesh, Japan, Russia, Lebanon and now South Africa and Nepal 30% • XultophyⓇ launched in Switzerland, the United Kingdom, Sweden, Hungary, Greece and now Cyprus 20% changing diabetes 10% 7% 0% 0 10 28% 28% 24% 20% 17% 15% 14% 13% 8% 3% 20 Months from launch Note: Limited IMS coverage in India Source: IMS Monthly value figures, August 2016 30 40 novo nordisk

View entire presentation